Abstract:
The present invention aims to provide an artificial tissue that can efficiently reproduce myocardial tissue function and that can be used in an actual implantation and produced by culturing. The present invention relates to a graft material for treating myocardial disease, the graft material including a cell sheet containing adipocytes.
Abstract:
The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin α2β1γ1, laminin α2β2γ1, laminin α1β1γ1 and laminin α1β2γ1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.
Abstract:
A method for treating a disease associated with tissue abnormality in a subject. The method includes administering an amount of a pharmaceutical composition to a subject in need of treating a disease associated with tissue abnormality, the pharmaceutical composition comprising a laminate comprising a fibrin gel and a cell culture. The laminate is produced by a method, which includes forming a fibrin gel layer on an upper surface of the cell culture by a reaction between fibrinogen and thrombin, wherein: the cell culture is prepared on a culture dish and the laminate of the fibrin gel and the cell culture are transferred onto a subject's heart. The laminate further includes a reinforcing portion made of a fibrin gel, the reinforcing portion formed by laminating the fibrin gel on the fibrin gel layer of the laminate of the cell culture and the fibrin gel.
Abstract:
An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.
Abstract:
The present invention relates to an evaluation device 4 for evaluating the severity of pneumonia in a target patient, comprising: an acquisition unit 42 for acquiring a respiratory waveform of the target patient; a calculation unit 43 for calculating a value of an index indicating instability of a respiratory cycle or a respiratory frequency from the respiratory waveform; and an evaluation unit 44 for evaluating the severity based on the calculated value.
Abstract:
A method is disclosed for cryopreservation of cardiocytes derived from pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow, the method maintaining the function of the cardiocytes derived from differentiated pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow, and yet reducing the possibility for tumorigenesis of undifferentiated pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow. A method is also disclosed for cryopreservation of cardiocytes derived from pluripotent stem cells or mesenchymal stem cells (derived from adipose tissue or bone marrow, the method including dissociating cells from a cell population which has been induced to differentiate into cardiocytes from pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow.
Abstract:
An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.
Abstract:
This invention relates to a prediction support system and associated methods for supporting prediction of the severity of a disease. The systems and methods may perform operations that include continuously detecting whether a patient with the disease is in bed, and acquiring, based on the detection result of the detecting, an in-bed pattern indicating, as a time series, whether the patient is in bed. The systems may include a detection device and an acquisition unit.
Abstract:
A heart failure diagnostic device includes a piezoelectric sensor sheet having flexibility and configured to output a detection signal corresponding to an input vibration. A respiratory signal acquisition unit is configured to extract, as a respiratory signal, a signal of a vibration frequency caused by respiration from the detection signal detected by the piezoelectric sensor sheet. A power spectrum calculator is configured to obtain a power spectrum of a respiratory frequency band from the respiratory signal, and a signal corrector is configured to correct the detection signal such that in the power spectrum, a maximum value of a first-order frequency component of a respiratory waveform is not smaller than 1.5 times a maximum value of a second-order frequency component of the respiratory waveform to obtain the respiratory signal.
Abstract:
Methods are disclosed of freezing, cryopreserving, and transferring a frozen sheet-shaped cell culture. The method of freezing includes (1) a step of immersing in a cryopreservation solution a sheet-shaped cell culture supported by a mesh-shaped support body; (2) a step of removing the cryopreservation solution adhered to the sheet-shaped cell culture, while keeping the sheet-shaped cell culture supported by the mesh-shaped support body; (3) a step of enclosing the sheet-shaped cell culture in a cold-resistant film, an upper surface and a lower surface of the sheet-shaped cell culture being covered by the mesh-shaped support body; and (4) a step of freezing the sheet-shaped cell culture.